Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aptorum Group Ltd Cl A (APM)

Aptorum Group Ltd Cl A (APM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 87,437
  • Shares Outstanding, K 34,022
  • Annual Sales, $ 910 K
  • Annual Income, $ 7,070 K
  • 60-Month Beta -0.21
  • Price/Sales 95.87
  • Price/Cash Flow 11.44
  • Price/Book 2.29
Trade APM with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.46 +2.03%
on 07/30/21
3.15 -20.32%
on 07/12/21
-0.62 (-19.81%)
since 07/02/21
3-Month
2.21 +13.57%
on 05/18/21
3.54 -29.10%
on 05/24/21
-0.13 (-4.92%)
since 04/30/21
52-Week
1.16 +116.38%
on 09/28/20
14.23 -82.36%
on 09/29/20
-1.28 (-33.77%)
since 07/31/20

Most Recent Stories

More News
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus

Regulatory News:

APM : 2.56 (-0.39%)
Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

Regulatory News:

APM : 2.56 (-0.39%)
Aptorum Group CEO Subscribed Shares In The Company

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group", the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to address global...

APM : 2.56 (-0.39%)
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma

Regulatory News:

APM : 2.56 (-0.39%)
Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference

Regulatory News:

APM : 2.56 (-0.39%)
Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum's Novel Preclinical Candidate Targeting Woman's Gynecological Conditions

Regulatory News:

APM : 2.56 (-0.39%)
Aptorum Group Limited Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

Regulatory News:

APM : 2.56 (-0.39%)
Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases

Regulatory News:

APM : 2.56 (-0.39%)
Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced financial...

APM : 2.56 (-0.39%)
Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

Regulatory News:

APM : 2.56 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Aptorum Group Limited is a pharmaceutical company. It engaged in developing and commercializing therapeutic and diagnostic technologies to tackle unmet medical needs. The company's therapeutic and diagnostic project primarily includes neurology, infectious diseases, gastroenterology, oncology and other...

See More

Key Turning Points

3rd Resistance Point 2.80
2nd Resistance Point 2.71
1st Resistance Point 2.64
Last Price 2.56
1st Support Level 2.48
2nd Support Level 2.39
3rd Support Level 2.32

See More

52-Week High 14.23
Fibonacci 61.8% 9.24
Fibonacci 50% 7.69
Fibonacci 38.2% 6.15
Last Price 2.56
52-Week Low 1.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar